Allakos Inc

NASDAQ ALLK

Download Data

Allakos Inc Sales to Fixed Assets Ratio 3 year CAGR for the quarter ending March 31, 2024

Allakos Inc Sales to Fixed Assets Ratio 3 year CAGR is NA for the quarter ending March 31, 2024. Sales to fixed assets ratio measures the revenue generated by a company relative to its fixed assets, such as property, plant, and equipment. It is calculated by dividing the revenue by the net value of fixed assets. This ratio provides insights into the efficiency of the company's fixed assets in generating sales revenue. A higher sales to fixed assets ratio suggests better sales generation from fixed assets and efficient utilization of physical infrastructure. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Allakos Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2023 was 0.00, a 0.00% change year over year.
  • Allakos Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2022 was 0.00, a 0.00% change year over year.
  • Allakos Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2021 was 0.00, a 0.00% change year over year.
  • Allakos Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2020 was 0.00, a 0.00% change year over year.
NASDAQ: ALLK

Allakos Inc

CEO Dr. Robert Alexander Ph.D.
IPO Date July 19, 2018
Location United States
Headquarters 975 Island Drive, Redwood City, CA, United States, 94065
Employees 131
Sector Healthcare
Industry Biotechnology
Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

CRBU

Caribou Biosciences Inc

NA

NA

KURA

Kura Oncology Inc

NA

NA

NXTC

NextCure  Inc

NA

NA

GTHX

G1 Therapeutics Inc

NA

NA

HRTX

Heron Therapeuti

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email